Accera Announces 75% AD Patient Enrolment in Phase 3 NOURISH Study

Accera Announces 75% AD Patient Enrolment in Phase 3 NOURISH Study
Accera, Inc. a clinical-stage biotechnology company based in Broomfield, Colorado, recently announced that 75% of patients have been enrolled in its NOURISH AD Phase 3 clinical trial assessing the efficacy of its investigational compound AC-1204 for the treatment of Alzheimer's disease (AD). The company is expecting to enroll a total of  480 AD patients for the first of two Phase 3 clinical studies evaluating AC-1204, a drug aimed to address the metabolic brain deficiencies found in patients with AD. "The NOURISH AD trial is progressing well, and we expect to complete enrollment mid-next year," said in a recent press release Accera's President and CEO, Dr. Charles Stacey. "The repeated failure of pipeline drugs for Alzheimer's disease emphasizes the need to explore new mechanisms in order to identify new options for patients. The NOURISH AD study represents a differentiated approach to tackling this disease." "Instead of addressing amyloid or tau, AC-1204 addresses the metabolic defects seen in the disease," added in the press release Samuel Henderson, Ph.D., Accera's vice president of research and development and the study's director. "The only way we can beat Alzheimer's is by testing n
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *